Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.
about
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesRole of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in ChildrenCurrent and emerging strategies for the prevention of graft-versus-host diseaseOral complications in hematopoietic stem cell recipients: the role of inflammationThe Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical OverviewInternational, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Recent advances in the management of graft-versus-host disease.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell TransplantPharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part IApproaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationEfficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].Cyclosporine use in hematopoietic stem cell transplantation: pharmacokinetic approach.Haploidentical Bone Marrow Transplantation in 2015 and Beyond.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.Cutaneous manifestations of graft-versus-host disease: role of the dermatologist.Cyclosporine Plus Methotrexate or Cyclosporine Plus Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Acute Leukemia Transplant: Comparison of Toxicity, Engraftment Kinetics and Transplant Outcome.The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation.The association between platelet transfusion and idiopathic pneumonia syndrome is unaffected by platelet product type.Is It Time to Reconsider the Lipopolysaccharide Paradigm in Acute Graft-Versus-Host Disease?Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients.Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.Advances in umbilical cord blood transplant: an overview of the 12th International Cord Blood Symposium, San Francisco, 5-7 June 2014.'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Numerical impairment of nestin(+) bone marrow niches in acute GvHD after allogeneic hematopoietic stem cell transplantation for AML.Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.
P2860
Q26751959-F78DB9ED-A087-4489-898B-80158A87EAD7Q26798470-A94D941F-CC6D-4A6D-A089-B544ACEFB85EQ27016541-62BDDDDB-7A8E-401F-AC50-0081A02DE6E5Q27027650-3B1329F4-5EF1-49C9-8BD8-8F2CE6E4A3D7Q28066083-75F3B487-C144-4E47-996C-F9598374883EQ30994673-EEBFB174-4E5E-41EC-AD8B-1CC648057758Q33419003-05A0BEBF-A525-47A3-9F7C-B4CF34A0BBE5Q33625948-F1D8CFB4-A0A9-4427-908F-5C3C43BC0FB1Q34428890-B046CFFD-D651-43F1-9F48-480A6E1622D3Q35499395-530426D5-758B-470D-A65B-AE6A043A31B5Q35975019-37F015A9-C644-4A66-8F71-8F9B796F0CA7Q36777485-09564301-2490-48CB-B398-7251503B9C18Q36777599-D1223BCC-91FF-482F-8133-F98C0DCA7D08Q36891433-23DDB935-9C98-4980-9681-205E8D850D08Q37076418-8BA90A9D-24C6-468A-A915-0E5EA9F0030FQ37178100-EAA17A97-F2FB-46CA-8390-9215FB49E397Q37536445-C36B7323-D39D-4972-AF64-C227B680FBFFQ38382105-46125356-A6C7-4469-B72C-F5C143A0F3FDQ38562065-1F6D8CDD-8057-431A-99FD-0ADD77813835Q38607242-6DDF6BAD-DED9-4E6F-9895-A311AC086777Q38735833-96B7D1F1-8EA2-494E-9BA5-E2587BEBA597Q38773356-D5D09325-985F-48EB-AD63-6FD7525048B6Q38790014-6C2C7192-0231-4001-BFC7-BE58EDB12067Q38827908-BE6A8A16-1293-47BF-80B3-1796D6A2B1CEQ38829335-E23F8363-3B5C-48E2-AFD8-BCC1AF19AE9BQ38961868-5BA7C5D5-092B-4086-8173-5CAF32AB8B44Q40096414-D7A4389E-D371-4F81-A685-95A430019E39Q40396484-00CDD2B8-6350-46AB-8547-3A0653D929B9Q40966054-A948AC4D-E8A7-44BD-8F76-5C0E30E0E80BQ41264625-649E359E-09F0-4BF9-9FAF-13273D9C0CD7Q41355730-ECD8B512-43CA-44BB-9056-DD2ABC7960A8Q41394915-6B72B3C2-6DDB-40D1-860A-8D667C3CA6EDQ41932903-548048B7-A321-46D0-AC56-43F919E62284Q43668394-40F04F27-261D-4E15-AC82-0FCEBAE2D47DQ48102813-BFDD18F1-5F87-4AB6-A92F-50039B2E0413Q48142819-8ACE02DB-6A51-47F0-B0F9-27AFCD58F6E1Q49332656-FE3FD420-DA32-4109-BBD0-04C1E871BBEDQ49384876-4B67EE85-B9AC-45D8-8378-3DF15FC73452Q49806345-FB8807A8-3DAB-4F70-BCE7-C00BF43C476BQ50115590-055299A8-FF62-43B1-B193-DC196C4AB600
P2860
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prophylaxis and treatment of G ...... s for a standardized practice.
@en
Prophylaxis and treatment of G ...... s for a standardized practice.
@nl
type
label
Prophylaxis and treatment of G ...... s for a standardized practice.
@en
Prophylaxis and treatment of G ...... s for a standardized practice.
@nl
prefLabel
Prophylaxis and treatment of G ...... s for a standardized practice.
@en
Prophylaxis and treatment of G ...... s for a standardized practice.
@nl
P2093
P2860
P50
P356
P1476
Prophylaxis and treatment of G ...... ns for a standardized practice
@en
P2093
A Bacigalupo
A Gratwohl
A Lawitschka
D Niederwieser
J Apperley
P2860
P2888
P304
P356
10.1038/BMT.2013.107
P407
P577
2013-07-29T00:00:00Z